Adaptive Biotechnologies (ADPT) Expected to Post Earnings on Wednesday

Adaptive Biotechnologies (NASDAQ:ADPT) will likely be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Adaptive Biotechnologies to announce earnings of ($0.0911) per share and revenue of $71.57 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $25.06 on Tuesday. The firm’s fifty day simple moving average is $26.36 and its 200 day simple moving average is $19.68. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. Adaptive Biotechnologies has a twelve month low of $12.00 and a twelve month high of $30.74.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. National Bank Financial set a $34.00 target price on Adaptive Biotechnologies in a research report on Tuesday, September 22nd. The Goldman Sachs Group began coverage on Adaptive Biotechnologies in a research report on Tuesday, September 29th. They set a “buy” rating and a $35.00 price target on the stock. TD Cowen upped their price target on Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Finally, Morgan Stanley lifted their price objective on shares of Adaptive Biotechnologies from $22.00 to $27.00 and gave the company an “equal weight” rating in a research note on Monday, October 12th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $30.06.

Insiders Place Their Bets

In related news, Director Robert Hershberg sold 30,664 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $24.40, for a total value of $748,201.60. Following the transaction, the director owned 46,683 shares in the company, valued at approximately $1,139,065.20. The trade was a 39.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Peter Neupert sold 124,690 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $25.15, for a total value of $3,135,953.50. Following the completion of the transaction, the director directly owned 130,625 shares of the company’s stock, valued at $3,285,218.75. This represents a 48.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 1,027,001 shares of company stock valued at $26,186,445. Insiders own 5.70% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.